The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data
Abstract
AIMS: The non-benzodiazepine hypnotics zolpidem and zopiclone, which are indicated for short-term treatment of insomnia, were considered originally by physicians as almost devoid of abuse and dependence potential. Several recent publications, however, have suggested that both agents carry a significant risk of abuse. To substantiate and re-evaluate this situation, the world literature was reviewed for cases of dependence of both agents; these cases were analysed in order to identify certain underlying patterns, if evident. METHODS: A systematic review based on a Medline literature search was conducted including the years 1966-2002 to assemble all available clinical case reports that were analysed for typical features of abuse and dependence according to prespecified criteria. Only case reports were of interest, and clinical studies were excluded. No limitations as to language or publication year were applied. The terms 'zolpidem', 'zopiclone' and 'abuse', 'dependence', 'addiction', 'withdrawal' and 'intoxication' were used to identify relevant publications. Potentially relevant citations were retrieved and assessed for inclusion independently by two authors. RESULTS: A total of 36 cases for zolpidem were identified, most of them reported in recent years, and 22 cases for zopiclone. Both sexes were involved to a similar extent; and cases were reported in all age groups. In extreme cases, dose increases reached a factor of 30-120 above the recommended doses. The majority of patients had a history of former drug or alcohol abuse and/or other psychiatric conditions. CONCLUSION: On the basis of world-wide prescription numbers, which are approximately twofold higher for zolpidem (1,338,774,000 tablets from June 2001 to June 2002 in Europe, Japan and United States) than for zopiclone (664,897,000 tablets during the same period in Europe and Japan), the relative incidence of reported dependence similar for both drugs and remarkably lower than that of benzodiazepines used for the treatment of disturbed sleep. The findings offer the conclusion that zolpidem and zopiclone are relatively safe drugs. However, as both drugs are psychotropic drugs, patients with a history of abuse or dependence and those with psychiatric diseases seem to be at increased risk of abuse of these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence 9 28 suggests that zopiclone carries a potential for dependence.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [28]
In the citing paper
“This elevated risk among older adults is partly attributed to the higher prevalence of sleep and mood disorders in this population, as well as to age-related reductions in drug clearance.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [28]
In the citing paper
“Studies 28 have shown that a history of psychiatric illness, as well as concurrent use of alcohol or other substances, significantly increases the risk of Z-drug misuse.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [28]
In the citing paper
“Psychiatric comorbidities are common among individuals with Z-drug use disorder, particularly depressive, anxiety, and personality disorders.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [28]
In the citing paper
“In addition to their therapeutic potential, these medications also have reinforcing properties (1–3) and thus can be misused”
From Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health (2023) · cites this paper as [1]
Citations
Cites
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R. W., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,255
Ward, A., & Clissold, S. P. (1987) · Drugs · doi:10.2165/00003495-198734010-00003 · Cited by 1,761
Siegel, R. S., & WEIDEN, I. (1968) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-196811000-00016 · Cited by 671
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
A prospective study of mortality among drug misusers during a 4‐year period after seeking treatment
Gossop, M., Stewart, D., Treacy, S., & Marsden, J. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00079.x · Cited by 311
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 302
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Epidemiological Evidence for a Low Abuse Potential of Zolpidem
Soyka, M., Bottlender, R., & Möller, H.-J. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-11224 · Cited by 249
Use and Abuse of the Benzodiazepines
Fraser, A. D. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199810000-00007 · Cited by 243
Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
LADER, M. H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00051-6 · Cited by 218
Research works printed but not linked: 10
- Alvarez M. D., 1994, Zopiclona: estudio de postcomercializacion en Espana [Zopiclone: postmarketing study in Spain], Psiquis, 15, 17
- Arzneimittelkommission der deutschen Ärzteschaft, 1999, Keine Verordnung von Zolpidem bei bekannter Benzodiazepinabhängigkeit [No prescription of zolpidem in known benzodiazepine dependence], Deutsches Ärzteblatt, 96, B
- Chamorro‐Garcia L., 1996, Depencia de zolpidem [Zolpidem dependence], Medicina Clinica, 106, 478
- Clarenbach P., 1995, Recommendations for the diagnosis and therapy of insomnia, Nervenarzt, 66, 723
- Harter C., 1999, Entwicklung eines Entzugsdelirs nach Abhängigkeit von Zolpidem und Zopiclon [Development of drug withdrawal delirium after dependence on zolpidem and zoplicone], Psychiatrische Praxis, 26, 309.
- Hofmann M., 1998, Ungestilltes Verlangen: Abhängigkeitssyndrom von Zolpidem (Stilnox) [Unsatisfied craving: zolpidem (Stilnox) dependence syndrome], Psychiatrische Praxis, 25, 313.
- Keup W., 1999, Zolpidem und Zopiclon. Geringeres Missbrauchspotential im Vergleich zu Benzodiazepin‐Hypnotika [Zolpidem and zopiclone. Lower abuse potential in comparison to benzodiazepine hypnotics], Arzneimitteltherapie, 16, 243
- Sanchez L. G., 1996, ], American Journal of Health-System Pharmacy, 53, 26
- 10.1136/bmj.317.7151.146 · DOI
- Sutherland J. C., 1991, ], New Zealand Medical Journal, 104, 103
Cited by
Sorted by citations
Items 101–200 of 409
Zusammenhang zwischen Verschreibungsverhalten der Ärzte und Medikamentenabhängigkeit ihrer Patienten
Holzbach, R., Martens, M., Kalke, J., & Raschke, P. (2010) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-010-1029-8 · Cited by 30
Rasu, R. S., Shenolikar, R. A., Nahata, M. C., & Balkrishnan, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.12.008 · Cited by 30
Treatment of sleep disorders in elderly patients
Harrington, J. J., & Avidan, A. Y. (2005) · Current Treatment Options in Neurology · doi:10.1007/s11940-005-0027-x · Cited by 30
“Despite that these agents are thought to have lower abuse and/or dependency potential compared to more traditional hypnotics, they should be prescribed cautiously in those with a history of substance abuse or psychiatric disorders [ 32 ].”
BackgroundDrug Misuse and Diversion in Adults Prescribed Anxiolytics and Sedatives
McLarnon, M. E., Monaghan, T. L., Stewart, S. H., & Barrett, S. P. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.3.262 · Cited by 29
Shbair, M. K. S., Eljabour, S., & Lhermitte, M. (2010) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2010.05.002 · Cited by 29
“[74] Hajak G, Muller WE, Wittchen Hu, Pittrow D, Kirch W.”
Current Patterns and Future Directions in the Treatment of Insomnia
Winkelman, J. W., & Pies, R. W. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590905344 · Cited by 29
“Finally, there have been some reports of abuse, dependence, and withdrawal associated with zolpidem, particularly in individuals with a history of drug or alcohol abuse (122).”
BackgroundHoffmann, F., Hies, M., & Glaeske, G. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2013 · Cited by 28
“Additionally, intravenous use of zopiclone has been described.(22) A recent case report described a patient with multiple sclerosis and paraspasticity taken 700–800mg zolpidem per day because of perceived myorelaxation.”
BackgroundHypnosedative Use and Predictors of Successful Withdrawal in New Patients Attending a Falls Clinic
Joester, J., Vogler, C., Chang, K., & Hilmer, S. N. (2010) · Drugs & Aging · doi:10.2165/11584480-000000000-00000 · Cited by 28
“In addition, BZ/Z drugs cause dependence,([4,5]) which may contribute to difficulties with attempts at discontinuation.”
BackgroundMachado, F. V., Louzada, L. L., Cross, N. E., Camargos, E. F., Dang‐Vu, T. T., & Nóbrega, O. D. T. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110962 · Cited by 28
The French addictovigilance network clinical assessment: Z-drugs, true false twins
Rousselet, M., Feuillet, F., Gérardin, M., Jolliet, P., Hardouin, J.-B., & Victorri‐Vigneau, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1346084 · Cited by 26
“One study on post-marketing surveillance reports about zolpidem failed to show differences according to gender [16].”
BackgroundFach, M., Bischof, G., Schmidt, C., & Rumpf, H. (2007) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.01.016 · Cited by 26
Modafinil and Zolpidem Use by Emergency Medicine Residents
McBeth, B. D., McNamara, R. M., Ankel, F., Mason, E. J., Ling, L. J., Flottemesch, T. J., & Asplin, B. R. (2009) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2009.00586.x · Cited by 25
Correlates of Dependence and Beliefs About the Use of Hypnotics Among Zolpidem and Zopiclone Users
Yen, C., Yen, C., Ko, C., Hwang, T., Chen, C., Chen, T., Su, P., Chen, S., & Lin, J. (2014) · Substance Use & Misuse · doi:10.3109/10826084.2014.980955 · Cited by 26
“One post-marketing surveillance report shows similar rates of zolpidem abuse among men and women in all age groups (Hajak et al., 2003).”
BackgroundResultInfluentialZolpidem stimulant effect: Induced mania case report and systematic review of cases
Sabé, M., Kashef, H., Gironi, C., & Sentissi, O. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109643 · Cited by 25
2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands
Wilson, K. J., van Niel, M. B., Cooper, L. C., Bloomfield, D., O'Connor, D. V., Fish, L. R., & MacLeod, A. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.098 · Cited by 25
Review of Insomnia Pharmacotherapy Options for the Elderly: Implications for Managed Care
Taylor, S. R., & Weiss, J. S. (2009) · Population Health Management · doi:10.1089/pop.2008.0047 · Cited by 23
“56,58 Therefore, the DEA did not classify ramelteon as a scheduled drug.”
What's wrong with prescribing hypnotics?
(2004) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2004.421289 · Cited by 24
Moree, W. J., Li, B.-F., Zamani-Kord, S., Yu, J., Coon, T., Huang, C., Marinkovic, D., Tucci, F. C., Malany, S., BRADBURY, M. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.117 · Cited by 24
Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess
Liao, K., Lin, C., Lai, S., & Chen, W. (2015) · Medicine · doi:10.1097/md.0000000000001302 · Cited by 23
Bejarano‐Romero, F., Piñol, J. L., Gilabert, N. M., Luque, P. C., López, N. B., & Basora, J. (2008) · Atención Primaria · doi:10.1016/s0212-6567(08)75695-6 · Cited by 23
“65-74 años 175 13,9 (12,1-16,0) 386 29,4 (26,9-31,9) < 0,001”
Yen, C.-F., Ko, C.-H., Chang, Y.-P., Yu, C.-Y., Huang, M.-F., Yeh, Y.-C., Lin, J.-J., & Chen, C.-S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12147 · Cited by 22
BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., & Marinelli, E. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917145636 · Cited by 22
Keuroghlian, A. S., Barry, A. S., & Weiss, R. D. (2012) · American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00273.x · Cited by 22
Istvan, M., Caillet, P., Rousselet, M., Guerlais, M., Laforgue, E., Gérardin, M., Jolliet, P., Feuillet, F., & Victorri‐Vigneau, C. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14753 · Cited by 26
“Case report reviews of abuse, misuse and dependence have reported the same proportion of men and women.(3,35) With respect to pharmacological differences, the pharmacokinetics of zolpidem appeared to be related to endocrine factors associated with CYP3A4 metabolism, suggesting higher plasma levels of zolpidem in women.”
ResultAdvances in the management of insomnia
Zhdanova, I. V. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.7.1573 · Cited by 22
Cho, C., Jee, H., Nam, Y.-J., An, H., Kim, L., & Lee, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61694-9 · Cited by 26
Pfeiffer, P. N., Ganoczy, D. A., Zivin, K., Gerlach, L. B., Damschroder, L. J., & Ulmer, C. S. (2023) · Sleep Health · doi:10.1016/j.sleh.2023.07.002 · Cited by 23
‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse
Orsolini, L., Chiappini, S., Grandinetti, P., Bruschi, A., Testa, R., Provenzano, A., Berardis, D. D., & Volpe, U. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.367 · Cited by 24
“In fact, despite the minimal abuse potential showed by initial reports, zolpidem abuse and dependence have been increasingly recorded in multiple case reports and case series [14,16,17], especially at very high doses, amongst subjects with a history of drug and/or alcohol addiction, and through idiosyncratic intake mo…”
BackgroundNHG-Standaard Slaapproblemen en slaapmiddelen
Neven, A. K., Lucassen, P. L., Bonsema, K., Teunissen, H., Verduijn, M. M., & Bouma, M. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_30 · Cited by 21
Dependence syndrome and intoxication delirium associated with zolpidem.
Sharan, P., Bharadwaj, R. S., Grover, S., Padhy, S. K., Kumar, V., & Singh, J. (2007) · PubMed · Cited by 21
Hochverbrauch von Zolpidem und Zopiclon: Querschnittsstudie auf Basis von Krankenkassendaten
Hoffmann, F., Pfannkuche, M., & Glaeske, G. (2008) · Der Nervenarzt · doi:10.1007/s00115-007-2280-6 · Cited by 21
“1200 mg Zolpidem pro Tag beobachtet [5, 11].”
BackgroundThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Zhang, X., Ma, Z. G., Rowlands, D. K., Gou, Y., Fok, K. L., Wong, H. Y., Yu, M., Tsang, L. L., Mu, L., Chen, L., et al. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/758097 · Cited by 20
High-Dose Zolpidem Dependence in a Patient with Chronic Facial Pain
Krueger, T. H. C., Kropp, S., & Huber, T. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e520 · Cited by 20
Clinical Sleep–Wake Disorders II: Focus on Insomnia and Circadian Rhythm Sleep Disorders
Spiegelhalder, K., Nissen, C., & Riemann, D. W. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_40 · Cited by 20
Sullivan, S. S. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.02.012 · Cited by 20
Nutt, D. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051988 · Cited by 20
“One is a review of all cases of dependence on Z-drugs that reported a German doctors prescription event study demonstrating the relative risk of Z-drugs misuse to be one third that of benzodiazepine hypnotics (Hajak et al., 2003).”
BackgroundZolpidem dependence, abuse and withdrawal: A case report.
Heydari, M., & Isfeedvajani, M. S. (2013) · Europe PMC (PubMed Central) · Cited by 20
The antinociceptive effect of zolpidem and zopiclone in mice
Pick, C. G., CHERNES, Y., Rigai, T., Rice, K. C., & Schreiber, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.013 · Cited by 21
Panin, F., & Peana, A. T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01164 · Cited by 21
High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review
Shukla, L., Chattopadhyay, A., Kandasamy, A., & Benegal, V. (2016) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_80_14 · Cited by 19
Olsson, M. O., Öjehagen, A., Brådvik, L., Kronstrand, R., & Håkansson, A. (2017) · Journal of Addiction · doi:10.1155/2017/6716929 · Cited by 19
Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway
Kjosavik, S. R., Ruths, S., & Hunskaar, S. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1124-2 · Cited by 21
“Although proper use of these drugs effectively relieves symptoms, benzodiazepine (BZD) anxiolytics and hypnotics as well as z-hypnotics are considered addictive by the Norwegian Medicines Agency due to side effects such as development of tolerance, risk of misuse, and dependence [1, 2].”
BackgroundJones, A. W., & Holmgren, A. (2012) · Forensic Science International · doi:10.1016/j.forsciint.2012.05.008 · Cited by 18
“Moreover, depressant drugs have a high abuse potential, as exemplified by barbiturates and benzodiazepines that also bind to the GABAA receptor complex in a similar way to the z-hypnotics [13,26,27].”
Der Gebrauch von Medikamenten mit Abhängigkeitspotenzial in Deutschland
Buth, S., Holzbach, R., Rosenkranz, M., & Verthein, U. (2017) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-017-2571-4 · Cited by 18
Lack of inhibition leads to abuse
Riegel, A. C., & Kalivas, P. W. (2010) · Nature · doi:10.1038/463743a · Cited by 18
Schwienteck, K. L., Li, G., Poe, M. M., Cook, J. M., Banks, M. L., & Negus, S. S. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4615-8 · Cited by 17
“These preclinical results also agree with the classification of zolpidem as a scheduled IV substance by the US Drug Enforcement Administration (DEA) and with evidence for zolpidem abuse by humans (Griffiths and Johnson 2005; Hajak et al. 2003).”
Roehrs, T., & Roth, T. G. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.04.010 · Cited by 17
Gérardin, M., Rousselet, M., Caillet, P., Grall‐Bronnec, M., Loué, P., Jolliet, P., & Victorri‐Vigneau, C. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027443 · Cited by 17
Riemann, D. W., & Hajak, G. (2009) · Der Nervenarzt · doi:10.1007/s00115-009-2746-9 · Cited by 17
Self-citationZopiclone withdrawal: an unusual cause of delirium in the elderly
Wong, C. P., Chiu, P. K. C., & Chu, L. W. (2005) · Age and Ageing · doi:10.1093/ageing/afi132 · Cited by 16
“Reported symptoms of zopiclone withdrawal range from anxiety, tachycardia, tremor, sweating, rebound insomnia, flushes and palpitations to derealisation, convulsion and delirium [1].”
BackgroundChung, S., Park, B., Yi, K., & Lee, J. S. (2013) · Sleep Medicine Research · doi:10.17241/smr.2013.4.2.51 · Cited by 16
Patterns of zolpidem use among Iraq and Afghanistan veterans: A retrospective cohort analysis
Shayegani, R., Song, K., Amuan, M. E., Jaramillo, C. A., Eapen, B. C., & Pugh, M. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190022 · Cited by 17
Jehle, J., Ficker, E. K., Wan, X., Deschênes, I., Kisselbach, J., Wiedmann, F., Staudacher, I., Schmidt, C., Schweizer, P. A., Becker, R., et al. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12002 · Cited by 15
“13 mM) have been reported (Hajak et al., 2003; Jones et al., 2007).”
BackgroundInfluentialBenzodiazepine and hypnotic prescribing in an acute adult psychiatric in-patient unit
Hallahan, B. P., Murray, I. T., & McDonald, C. (2009) · Psychiatric Bulletin · doi:10.1192/pb.bp.107.018382 · Cited by 16
“There is also some evidence that non- benzodiazepine hypnotic agents such as zopiclone and zolpidem can lead to misuse and dependence if prescribed for extended periods (Hajak et al, 2003).”
BackgroundJang, Y., Song, I., Oh, I., & Shin, J.-Y. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2563-9 · Cited by 17
A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia
Staner, L., Danjou, P., & Luthringer, R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.197 · Cited by 15
Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients
Lugoboni, F., Mirijello, A., Morbioli, L., Faccini, M., Casari, R., Cosmo, S. D., Gasbarrini, A., & Addolorato, G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1628216 · Cited by 15
Zolpidem Withdrawal Delirium: A Case Report
Aggarwal, A., & Sharma, D. D. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.4.451.e27 · Cited by 14
Dahlman, D., Abrahamsson, T., Kral, A. H., & Håkansson, A. (2016) · Journal of Addiction · doi:10.1155/2016/9298571 · Cited by 14
Evaluation of Trazodone and Quetiapine for Insomnia
Doroudgar, S., Chou, T. I.-F., Yu, J., Trinh, K., Pal, J., & Perry, P. J. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13m01558 · Cited by 14
“14 17 Additionally, due to the habit-forming nature of benzodiazepines and non–benzodiazepine hypnotics, other agents are often used first-line for patients’ insomnia.”
BackgroundSedative-Hypnotics Are Widely Abused by Drivers Apprehended for Driving Under the Influence of Drugs
Kriikku, P., Hurme, H., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J., & Ojanperä, I. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000138 · Cited by 15
Quetiapine Treatment of Zolpidem Dependence
Mariani, J. J., & LEVIN, F. R. (2007) · American Journal on Addictions · doi:10.1080/10550490701525467 · Cited by 14
Eszopiclone for the treatment of insomnia
Scharf, M. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.345 · Cited by 14
“Zolpidem and zopiclone have been shown to have a lower abuse and dependence potential than that of the benzodiazepines [66].”
BackgroundZopiclone misuse: an update from Dublin
Bannan, N., Rooney, S., & O’Connor, J. (2007) · Drug and Alcohol Review · doi:10.1080/09595230601052777 · Cited by 13
Pharmacotherapy for post-traumatic stress disorder
Alderman, C. P., McCarthy, L. C., & Marwood, A. C. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2.1.77 · Cited by 14
Non-medical use of olanzapine by people on methadone treatment
James, P. D., Fida, A. S., Konovalov, P., & Smyth, B. P. (2016) · BJPsych Bulletin · doi:10.1192/pb.bp.115.052886 · Cited by 12
Vukičević, T., Draganić, P., Škribulja, M., Puljak, L., & Došenović, S. (2023) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-023-02574-1 · Cited by 12
“The incidence of Z-drugs dependence is significantly lower than with benzodiazepines, and they are also relatively safe medicines [44].”
ZOLPIDEM: INTRAVENOUS MISUSE IN DRUG ABUSERS
Brunelle, E., Rotily, M., Lançon, C., Goisset, P., PIQUET, J. M., LAGADEC, G., & Vosgien, V. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01239.x · Cited by 12
Substanzinduzierte Schlafstörungen und Schlafmittelmissbrauch
Riemann, D. W., & Nissen, C. (2011) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-011-1374-2 · Cited by 12
Miyaguchi, H., & Kuwayama, K. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.08.058 · Cited by 12
Duncan, P. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781139025515.013 · Cited by 12
Prior Authorization of Newer Insomnia Medications in Managed Care: Is It Cost Saving?
Balkrishnan, R., Joish, V. N., Bhosle, M. J., Rasu, R. S., & Nahata, M. C. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26862 · Cited by 12
Jones, A. W., & Holmgren, A. (2012) · Journal of Safety Research · doi:10.1016/j.jsr.2012.05.002 · Cited by 11
Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6
Huang, C., Moree, W. J., Zamani-Kord, S., Li, B.-F., Tucci, F. C., Malany, S., Wen, J., Wang, H., Hoare, S. R. J., Yang, C. Z., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.053 · Cited by 11
Marković‐Peković, V., Stoisavljević-Šatara, S., & Škrbić, R. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0732-6 · Cited by 11
“This drug has been vigorously marketed worldwide, probably due its weaker dependence potential and relatively fewer side effects [26, 50 ], and there is a noticeable increasing trend in the utilization of these so-called z-hypnotics [21, 23, 27, 29, 34, 51].”
BackgroundSleep Related Amnestic Behaviors due to Zolpidem
Cubała, W. J., & Gabrielsson, A. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20130527020102 · Cited by 11
Lee, J. H., Park, H. N., Choi, J. Y., Kim, N. S., Park, H., Park, S. S., & Baek, S. Y. (2017) · Journal of Separation Science · doi:10.1002/jssc.201700879 · Cited by 11
Lohse, M., & Müller-Oerlinghausen, B. (2020) · Arzneiverordnungs-Report 2020 · doi:10.1007/978-3-540-69219-5_28 · Cited by 8
Flynn, A., & COX, D. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01448.x · Cited by 11
Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders
Wesson, D. R., Smith, D. E., Ling, W. W., & Sabnani, S. (2008) · doi:10.1002/9780470515167.ch64 · Cited by 11
Segawa, H., Iwata, Y. T., Okada, Y., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Kanamori, T. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15279 · Cited by 10
“Additionally, ZOP is believed to induce less physical dependence and addiction than benzodiazepines [2].”
BackgroundSchepis, T. S. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.04.018 · Cited by 10
Sedative-Hypnotics and Anxiolytics
Arnaout, B., & Petrakis, I. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_23 · Cited by 10
TOXINZ, the New Zealand Internet poisons information database: The first decade
Fountain, J. S., & Slaughter, R. J. (2016) · Emergency Medicine Australasia · doi:10.1111/1742-6723.12594 · Cited by 10
Polysomnographic Sleep Disturbances Due to High-Dose Zolpidem Use: A Case Report
Ohshima, H., Kotorii, N., Takii, M., Hiejima, H., Habukawa, M., Kuwahara, H., & Uchimura, N. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7500 · Cited by 11
Obara, K., Ao, L., Ogawa, T., Ikarashi, T., Yamaki, F., Matsuo, K., Yoshio, T., & Tanaka, Y. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00829 · Cited by 10
Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication
LADER, M. H. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_15 · Cited by 10
A case of Zolpidem dependence successfully detoxified with gabapentin
Fernandes, W. H., Pereira, Y. S., & Tereza, S. O. (2013) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.117152 · Cited by 10
Pawaskar, M. D., Joish, V. N., CAMACHO, F. T., Rasu, R. S., & Balkrishnan, R. (2008) · Journal of Medical Economics · doi:10.3111/13696990701817491 · Cited by 10
Zao Ren An Shen capsule for chronic insomnia
Birling, Y., Bensoussan, A., Sarris, J. J., Avard, N., & Zhu, X. (2019) · Medicine · doi:10.1097/md.0000000000014853 · Cited by 10
“Despite being themost common medication for insomnia,([18]) Benzodiazepine Receptor Agonists (BzRAs) have been found to induce a large range of adverse effects,([15,19]) have been associated with rebound insomnia and withdrawal symptoms,([20]) and there are concerns about dependence.([21,22]) Unsurprisingly, insomniac…”
BackgroundDai, N., Li, Y., Sun, J., Li, F., & Xiong, H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.537402 · Cited by 10
“Despite being the most common drugs for the treatment of insomnia (41), benzodiazepine receptor agonists have been found to have some adverse effects (38, 42), and there are also insomnia relapse, withdrawal symptoms (43), and concerns about dependence (44, 45).”
BackgroundEffects of Hypnotics on Sleep and Quality of Life in Insomnia
Alford, C., & Wilson, S. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-343-5_7 · Cited by 10
Zolpidem: Forensic Aspects for the Toxicologist and Pathologist
Rohrig, T. P., & Moore, C. M. (2005) · Forensic Science Medicine and Pathology · doi:10.1385/fsmp:1:2:081 · Cited by 10
Taha, E., Nour, S. A. E.-K., Mamdouh, W., & Naguib, M. J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124230 · Cited by 9
Progress in GABAA receptor agonists for insomnia disorder
Wang, W., Fu, W., Zhu, H., Ma, J., Zhang, J., & Qi, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432726 · Cited by 11
Sleep and Its Modulation by Substances That Affect GABAA Receptor Function
Steiger, A. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_5 · Cited by 9
“There exist some case reports on dependence after prolonged use of zolpidem in patients with a history of substance abuse [36].”
BackgroundEfficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia
Najib, J. S. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_18 · Cited by 9
Potential Antipsychotic Effects of Zolpidem
Wong, G. Y. M., Bastiampillai, T. J., & Dhillon, R. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903487290 · Cited by 9
“Caution, however, needs to be exercised due to emerging evidence of zolpidem abuse and dependence [5].”
BackgroundIdentification and characterization of new impurities in zopiclone tablets by LC-QTOF-MS
Xing, H., Cheng, F.-J., Di, B., Xu, H., Song, M. O., Hang, T., & Lu, Y. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114056 · Cited by 9
Metadata
- Authors
- Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W.
- Affiliations
- University of Regensburg (DE)
- Goethe University Frankfurt (DE)
- Technische Universität Dresden (DE)
- Corresponding author
- Hajak, G.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2003-10
- Volume
- 98
- Issue
- 10
- Pages
- 1371-1378
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2116289594
- Cited by
- 404
- References
- 74
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 19 · 2022: 11 · 2021: 16 · 2020: 29 · 2019: 21 · 2018: 17 · 2017: 13 · 2016: 25 · 2015: 13 · 2014: 27 · 2013: 19 · 2012: 20
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addiction (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- zolpidem, zopiclone, non-benzodiazepine hypnotics, drug addiction, drug abuse, insomnia treatment, benzodiazepine alternatives, prescribing patterns, psychiatric comorbidity, withdrawal, drug safety
- MeSH terms
- Zolpidem, Adult, Aged, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Piperazines, Pyridines, Substance-Related Disorders, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
